Abbott Laboratories stock gains as Citi lifts price target and guidance stays firm
Published on 09/11/2026 at 21:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Abbott Laboratories stock (ISIN US0028241000) is trading around USD 103 on the New York Stock Exchange on September 11, 2026, keeping the shares close to the lower end of their recent range while investors weigh raised 2026 EPS guidance of USD 5.45-5.60 against sector risks and valuation.
Citi’s Buy rating and upside potential
According to The Globe and Mail on September 11, 2026, Citi analyst Joanne Wuensch reiterated a Buy rating on Abbott Laboratories with a price target of USD 125.00, after the shares had recently closed at USD 105.23 close to a 52-week low of USD 99.71.
The same analyst overview reports that the average analyst price target on Abbott Laboratories currently stands at USD 124.33, implying a 17.6 percent upside from current levels and underpinning a Strong Buy consensus across the covering houses.The Globe and Mail
Latest quarterly figures and guidance for 2026
As MarketBeat summarized on September 11, 2026, Abbott Laboratories last reported quarterly results for the second quarter of 2026 on July 16, 2026, posting earnings per share of USD 1.31, which was USD 0.03 above the consensus estimate of USD 1.28.
In the same Q2 2026 report, Abbott Laboratories generated revenue of USD 12.59 billion, modestly ahead of analyst expectations of USD 12.52 billion and 13.0 percent higher than the USD 11.14 billion recorded in the comparable quarter a year earlier, highlighting solid top-line growth in the current year.MarketBeat
According to the Q2 2026 performance summary cited by MarketBeat, Abbott Laboratories delivered a net margin of 11.65 percent and a return on equity of 17.69 percent in Q2 2026, while revenue growth of 13.0 percent year on year supported management’s decision to raise full-year 2026 EPS guidance to a range of USD 5.45-5.60.
The same overview notes that Abbott Laboratories has also set guidance for Q3 2026 EPS at USD 1.38-1.46, and that research analysts currently forecast full-year 2026 EPS of about USD 5.52, which sits broadly mid-range within the company’s updated guidance band.MarketBeat
Risk factors balanced against growth drivers
The valuation and guidance story for Abbott Laboratories is complemented by a balanced risk assessment in the latest analyst commentary. As Zacks (via Yahoo Finance) wrote on September 11, 2026, Abbott’s shares have declined 18.9 percent over the past year, compared with a 28.9 percent decline for the broader Medical Products industry, reflecting relative resilience but also investor caution.
The same Zacks analyst blog highlights that Abbott’s Rapid and Molecular Diagnostics businesses remain exposed to volatility in respiratory testing volumes, that pricing policies in China continue to constrain growth in the Core Laboratory segment, and that the integration of the Exact Sciences oncology and screening platform brings financing and dilution risks even as it broadens the diagnostics portfolio.Zacks via Yahoo Finance
On the positive side, Zacks points out that Abbott’s diversified portfolio supports steady underlying growth across medical devices, glucose monitoring products such as FreeStyle Libre, and established pharmaceuticals, while the Nutrition segment shows sequential improvement as pricing actions, Women, Infants and Children (WIC) program wins and new products support a gradual recovery in volumes.Zacks via Yahoo Finance
Stock level and market metrics
Per recent NYSE trading data on Abbott Laboratories, the shares opened close to USD 103 on September 11, 2026, with the previous close reported around USD 103.37 on the last completed trading day and intraday moves keeping the stock within a tight band relatively close to its 52-week low of USD 99.71 and well below the USD 124.33 average analyst price target.MarketBeat
Abbott Laboratories stock key data
- Company: Abbott Laboratories Inc.
- ISIN: US0028241000
- Ticker: ABT
- Trading venue: NYSE
- Price (as of September 11, 2026): 103.37 USD
- Market capitalization: 180,000,000,000 USD (as of September 11, 2026)
- Sector / Industry: Health Care / Medical Devices and Diagnostics
- Index membership: S&P 500
- Next earnings date: October 14, 2026
